Privately-held Alloy Therapeutics has announced a new multi-year collaboration with Pfizer (NYSE: PFE) to develop a bespoke platform that will enhance the US pharma giant’s ability to discover antibodies against targets deemed difficult to address with existing antibody discovery technologies.
Alloy will receive an undisclosed upfront payment from Pfizer and be eligible for pre-specified preclinical to commercial milestones on products originating on the platform.
This is the latest in a string of partnership announcements for Alloy, with the company having announced collaborations with pharma majors Takeda (TYO: 4502) and Eli Lilly (NYSE: LLY) during 2024, and Sanofi (Euronext: SAN) earlier this year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze